This list reflects information regarding the applications as of the approval date. It is not updated with regard to applicant or application status changes. The applications are listed by date of approval in reverse chronological order.
|Tradename/Proper Name||Indication for Use||STN||Manufacturer/
|Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.||125736/0||Celgene Corporation, a Bristol-Myers Squibb Company
86 Morris Ave.
Summit, NJ 07901
Lic. # 2252
|Indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.||125714/0||Juno Therapeutics, Inc.
400 Dexter Avenue North
Seattle, WA 98109
Lic. # 2156